We have been writing about potential vaccines in late-stage trials — prophylactics intended to prevent Covid-19 disease and, ideally, infection with SARS-Cov-2. Another class of drugs is the therapeutics, such as the Regeneron “cocktail” the President received. The vaccines from … Continue reading →
Herewith three items of Covid-19 news you may have missed this week: Neurologic symptoms are common, wrinkles in vaccine distribution, and a tracker for the White House superspreader events. Plus the accustomed frippery. Neurologic symptoms are common A study in … Continue reading →
This week two Operation Warp Speed-supported vaccine makers began Phase III trials: Johnson & Johnson began enrolling 60,000 participants in the US and worldwide on Monday, and yesterday Novavax opened a 10,000-person trial in the UK. Johnson & Johnson / … Continue reading →
The Washington Post reports that the FDA will soon release tough new standards for granting emergency authorization for any Covid-19 vaccine — standards that all but guarantee that none could get the green light before mid-November. It looks to me … Continue reading →
Herewith three items of Covid-19 news you may have missed this week: solid evidence for airborne transmission; Warp Speed-supported vaccines will be free; and word that asymptomatic children can transmit the disease. Plus the usual frippery. It’s airborne Researchers at … Continue reading →
After pressure from scientists and public health experts, vaccine makers are releasing the detailed protocols for their Phase III vaccine trials. Moderna went first yesterday morning and Pfizer followed in the afternoon. The others will come around. These documents let … Continue reading →
Those of us who have been hoping that life can go back to some kind of normal after a vaccine is available may need to reset our expectations. The vaccines under development will protect against disease, not against infection. What … Continue reading →
Herewith three items of Covid-19 news you may have missed this week: an expert’s reflections on vaccines and bioethics, kidney damage in Covid-19, and a look at worldwide trends in confidence in vaccines. Plus a frippery. The bioethics of vaccine … Continue reading →
The biggest drawback to one of the vaccine candidates receiving an FDA Emergency Use Authorization: it would halt the Phase III trial and destroy any chance of getting more data about that vaccine’s safety, efficacy, and longevity. On the This … Continue reading →
Nine vaccine makers have signed an unprecedented pledge to conduct the search for a Covid-19 vaccine only “in accordance with high ethical standards and sound scientific principles,” in an attempt to bolster public confidence in any vaccine that emerges. Political … Continue reading →
